Development of novel precision medicine approach for management of heart failure with preserved ejection fraction

Important results from the project

Knowledge about subtypes and ethnic differences in patients with Heart failure with preserved ejection fraction (HFpEF) is limited. The project aimed to establish a precision medicine approach for HFpEF by deep-phenotyping patients in China and Sweden using advanced clinical assessments and omics. Patients have been characterized and molecularly phenotyped. Ongoing analyses aim to identify distinct subgroups of patients, directing future diagnosis and pharmacological interventions

Expected long term effects

The ultimate goal is to divide patients with Heart Failure with preserved ejection fraction into smaller disease segments that can be identified by unique molecular and/or imaging biomarkers. This will lead to a better understanding of which molecular pathways to pharmacologically target to treat the different patient subgroups and thereby enabling that the patients will be treated with the drug that has the best chances of improving his/hers condition, hence enabling precision medicine.

Approach and implementation

During the project, the China and Swedish teams have had regular meetings sharing experiences, progress and challenges in the ongoing studies. These regular virtual meetings and one face-to-face interaction have significantly advanced the project forward and fostered a strong collaboration between the teams. This spirit has been especially important in the project´s last six months when joint data analysis and writing of the first publication have taken place under tight timelines.